ReviewJournal of thrombosis and haemostasis : JTH2016
Role of hemostatic factors in hepatic injury and disease: animal models de-liver.
Review in Journal of thrombosis and haemostasis : JTH, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 47 citations in OpenAlex.
- Elevated FDP levels independently predict poor outcomes in HBV-ACLF patients treated with artificial liver support system therapy.Scientific reports · 2025Article
- Hemostatic Antimicrobial Hydrogels Based on Silicon, Iron, Zinc, and Boron Glycerolates for Wound Healing Applications.Gels (Basel, Switzerland) · 2024Article
- Treatment of portal vein thrombosis in cirrhosis with anticoagulation-more than meets the eye?Hepatobiliary surgery and nutrition · 2024Article
- Role of Perturbated Hemostasis in MASLD and Its Correlation with Adipokines.Life (Basel, Switzerland) · 2024Review
- Platelet adhesion assessed by PFA-100 is not linked to progression of ACLD.JHEP reports : innovation in hepatology · 2024Article
- Iron(III) Monoglycerolate as a New Biocompatible Precursor in the Synthesis of Bioactive Nanocomposite Glycerohydrogels.Current pharmaceutical biotechnology · 2024Article
- Isolation, culture, and delivery considerations for the use of mesenchymal stem cells in potential therapies for acute liver failure.Frontiers in immunology · 2023Review
- Non-alcoholic fatty liver disease fibrosis score is a useful index for predicting all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis.Frontiers in medicine · 2023Article
- Animal models applied to acute-on-chronic liver failure: Are new models required to understand the human condition?World journal of clinical cases · 2022Review
- Targeting von Willebrand factor in liver diseases: A novel therapeutic strategy?Journal of thrombosis and haemostasis : JTH · 2021Review
- Antifungal Activity and Acute and Repeated-Dose Toxicity Study of Geranyl Cinnamate Ester in Mice.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Applications of the microphysiology systems database for experimental ADME-Tox and disease models.Lab on a chip · 2020Article
- Review
- Colonic hydrogen sulfide produces portal hypertension and systemic hypotension in rats.Experimental biology and medicine (Maywood, N.J.) · 2018Article
- Lymphocytes contribute to biliary injury and fibrosis in experimental xenobiotic-induced cholestasis.Toxicology · 2017Article
- Dose-dependent effects of alpha-naphthylisothiocyanate disconnect biliary fibrosis from hepatocellular necrosis.Journal of biochemical and molecular toxicology · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Chronic liver damage is associated with unique changes in the hemostatic system. Patients with liver disease often show a precariously rebalanced hemostatic system, which is easily tipped towards bleeding or thrombotic complications by otherwise benign stimuli. In addition, some clinical studies have shown that hemostatic system components contribute to the progression of liver disease. There is a strong basic science foundation for clinical studies with this particular focus. Chronic and acute liver disease can be modeled in rodents and large animals with a variety of approaches, which span chronic exposure to toxic xenobiotics, diet-induced obesity, and surgical intervention. These experimental approaches have now provided strong evidence that, in addition to perturbations in hemostasis caused by liver disease, elements of the hemostatic system have powerful effects on the progression of experimental liver toxicity and disease. In this review, we cover the basis of the animal models that are most often utilized to assess the impact of the hemostatic system on liver disease, and highlight the role that coagulation proteases and their targets play in experimental liver toxicity and disease, emphasizing key similarities and differences between models. The need to characterize hemostatic changes in existing animal models and to develop novel animal models recapitulating the coagulopathy of chronic liver disease is highlighted. Finally, we emphasize the continued need to translate knowledge derived from highly applicable animal models to improve our understanding of the reciprocal interaction between liver disease and the hemostatic system in patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.